New immunotherapy mops up leftover leukemia cells
NCT ID NCT02458014
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia whose cancer was in remission but still had a few hidden cancer cells (minimal residual disease). The drug helps the immune system attack and destroy those leftover cells. The goal was to see if it could keep the cancer from coming back. The study found that blinatumomab improved relapse-free survival, meaning patients stayed in remission longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.